AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20841418 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg/min
Number of subjects: 75
Study 20841418 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 75
Study 18227530 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (part of CAF regimen)
Number of subjects: 180
Study 18227530 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 180
Study 18227530 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and fluorouracil (CAF)
Number of subjects: 180
Study 16606867 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive risk factor modification strategy (targeted treatment of hypertension, dyslipidaemia, homocysteine, haemoglobin and phosphate)
Number of subjects: 152
Study 16606867 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 152
Study 16606867 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive risk factor modification strategy
Number of subjects: 152
Study 12568834 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (conjugated equine estrogen and micronized progesterone)
Number of subjects: 55
Study 12568834 — intervention group
Group type: COMPARATOR
Intervention: Tacrine (initial dose of 40 mg/day increased up to 160 mg/day)
Number of subjects: 55
Study 12568834 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 55
Study 12568834 — intervention group
Group type: COMPARATOR
Intervention: Tacrine
Number of subjects: 55
Study 11342422 — intervention group
Group type: EXPERIMENTAL
Intervention: PMitCEBO (mitoxantrone, 7 mg/m2 IV on day 1)
Number of subjects: 516
Study 11342422 — intervention group
Group type: COMPARATOR
Intervention: PAdriaCEBO (adriamycin, 35 mg/m2 IV on day 1)
Number of subjects: 516
Study 11342422 — intervention group
Group type: EXPERIMENTAL
Intervention: PMitCEBO
Number of subjects: 516
Study 11342422 — intervention group
Group type: COMPARATOR
Intervention: PAdriaCEBO
Number of subjects: 516
Study 9444547 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/d
Number of subjects: 13
Study 9444547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7840553 — intervention group
Group type: COMPARATOR
Intervention: Dapsone monotherapy (68 patients)
Number of subjects: 307
Study 7840553 — intervention group
Group type: COMPARATOR
Intervention: Dapsone monotherapy
Number of subjects: 307
Study 7840553 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dapsone and rifampin
Number of subjects: 307
Study 7840553 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen (dapsone, rifampin, isoniazid, prothionamide)
Number of subjects: 307
Study 7840553 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 307
Study 3281706 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% silver sulphadiazine ophthalmic ointment
Number of subjects: 20
Study 3281706 — intervention group
Group type: COMPARATOR
Intervention: Miconazole 1%
Number of subjects: 20
Study 1721977 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 255
Study 1721977 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine
Number of subjects: 255
Study 1721977 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 255
Study 1721977 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 255
Study 412800 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine 200 mg
Number of subjects: 100
Study 412800 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine 30 mg
Number of subjects: 100
Study 31144590 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy plus brachytherapy
Number of subjects: 6643
Study 31144590 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy plus adjuvant radiation therapy
Number of subjects: 6643
Study 27284754 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (HPI; 0.6 g•kg‐1•bolus‐1)
Number of subjects: 8
Study 27284754 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein intake (MPI; 0.3 g•kg‐1•bolus‐1)
Number of subjects: 8
Study 25263630 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based DESI
Number of subjects: 0
Study 25263630 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-based DESI
Number of subjects: 0
Study 25263630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formats
Number of subjects: 0
Study 22788244 — intervention group
Group type: EXPERIMENTAL
Intervention: CLT-driven intervention with low-level construal (LLC)
Number of subjects: 411
Study 22788244 — intervention group
Group type: EXPERIMENTAL
Intervention: CLT-driven intervention with high-level construal (HLC)
Number of subjects: 411
Study 22788244 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 411
Study 21780185 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11) C]NPA
Number of subjects: 10
Study 21780185 — intervention group
Group type: EXPERIMENTAL
Intervention: Available % R(HIGH)
Number of subjects: 10
Study 19019980 — intervention group
Group type: EXPERIMENTAL
Intervention: False visual feedback of hand movements
Number of subjects: 0
Study 19019980 — intervention group
Group type: COMPARATOR
Intervention: Visual information
Number of subjects: 0
Study 17712241 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session HIV risk-reduction intervention during 16 weeks of outpatient cognitive behavioral SUD treatment
Number of subjects: 50
Study 17712241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 15121556 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally 6 to 8 hours after mifepristone 200 mg
Number of subjects: 1080
Study 15121556 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 800 microg vaginally 23 to 25 hours after mifepristone 200 mg
Number of subjects: 1080
Study 11605921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffing position
Number of subjects: 456
Study 11605921 — intervention group
Group type: COMPARATOR
Intervention: Simple head extension
Number of subjects: 456
Study 9608461 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial tension applied during ACL reconstruction (less than 80 N)
Number of subjects: 0
Study 9608461 — intervention group
Group type: EXPERIMENTAL
Intervention: Restressing of patellar tendon autografts
Number of subjects: 0
Study 9608461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic tensile loading
Number of subjects: 0
Study 9608461 — intervention group
Group type: EXPERIMENTAL
Intervention: Unphysiologically high tension
Number of subjects: 0
Study 9608461 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress shielding
Number of subjects: 0
Study 8049945 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with temporary arteriovenous fistula
Number of subjects: 0
Study 8049945 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 2525329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 5 mg twice daily
Number of subjects: 46
Study 2525329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg twice daily
Number of subjects: 46
Study 2525329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31953736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional 1550-nm erbium fiber laser
Number of subjects: 18
Study 31953736 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 18
Study 31053800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intereye asymmetry of FLV%
Number of subjects: 72
Study 31053800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intereye asymmetry of GLV%
Number of subjects: 72
Study 31053800 — intervention group
Group type: COMPARATOR
Intervention: Intereye asymmetry of perfused vessel density
Number of subjects: 72
Study 31053800 — intervention group
Group type: COMPARATOR
Intervention: Intraeye asymmetry of microvascular parameters and neural structure parameters
Number of subjects: 72
Study 31053800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intereye asymmetric parameters (FLV and GLV%)
Number of subjects: 72
Study 28662448 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to particles from toasting bread
Number of subjects: 54
Study 28662448 — intervention group
Group type: COMPARATOR
Intervention: Particles emitted from frying sausages and candle burning
Number of subjects: 54
Study 25249496 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min teacher-implemented classroom-based activity break (AB)
Number of subjects: 118
Study 22610748 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH (Schisandra fruit extract and sesamin)
Number of subjects: 40
Study 22610748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22117666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-morning snacking (10:30 am to 11:29 am)
Number of subjects: 123
Study 22117666 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more snacks per day
Number of subjects: 123
Study 22117666 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon snacking
Number of subjects: 123
Study 19877104 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) plus methotrexate (MTX)
Number of subjects: 0
Study 19877104 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 0
Study 16513448 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (300 mL daily for 10 days)
Number of subjects: 18
Study 16513448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (400 mg daily for 10 days)
Number of subjects: 18
Study 16513448 — intervention group
Group type: COMPARATOR
Intervention: Water (300 mL daily for 10 days)
Number of subjects: 18
Study 12762074 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive role for insurance case managers and workplace ergonomic interventions
Number of subjects: 0
Study 12762074 — intervention group
Group type: COMPARATOR
Intervention: Traditional case management routines (reference group)
Number of subjects: 0
Study 10624970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 10624970 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study 8937535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (75 to 400 mg daily)
Number of subjects: 56
Study 8937535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1569602 — intervention group
Group type: EXPERIMENTAL
Intervention: MTP‐PE 1 mg
Number of subjects: 30
Study 1569602 — intervention group
Group type: EXPERIMENTAL
Intervention: MTP‐PE 4 mg
Number of subjects: 30
Study 1569602 — intervention group
Group type: EXPERIMENTAL
Intervention: MTP‐PE
Number of subjects: 30
Study 3901676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 3901676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31425441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), mean daily dose 927 ± 209 mg/m²
Number of subjects: 23
Study 31425441 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm based on 3 PK sampling time points (C0, C1, C2)
Number of subjects: 23
Study 31425441 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of the algorithm in a randomized group of 6 patients
Number of subjects: 23
Study 28439633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystodistension
Number of subjects: 77
Study 28439633 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy
Number of subjects: 77
Study 27221208 — intervention group
Group type: EXPERIMENTAL
Intervention: IV brivaracetam (BRV) administered as a bolus (200 mg/day BID)
Number of subjects: 105
Study 27221208 — intervention group
Group type: EXPERIMENTAL
Intervention: IV brivaracetam (BRV) administered as an infusion (200 mg/day BID)
Number of subjects: 105
Study 27221208 — intervention group
Group type: COMPARATOR
Intervention: Oral brivaracetam (BRV) (200 mg/day)
Number of subjects: 105
Study 27221208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 105
Study 27221208 — intervention group
Group type: EXPERIMENTAL
Intervention: IV brivaracetam (BRV) (bolus or infusion)
Number of subjects: 105
Study 27221208 — intervention group
Group type: EXPERIMENTAL
Intervention: IV brivaracetam (BRV)
Number of subjects: 105
Study 25543176 — intervention group
Group type: EXPERIMENTAL
Intervention: Floseal® group (FG)
Number of subjects: 120
Study 25543176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 23512758 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change counselling developed from motivational interviewing, delivered by trained clinicians using the Talking Lifestyles programme.
Number of subjects: 1827
Study 23512758 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change counselling (intervention group).
Number of subjects: 1827
Study 23512758 — intervention group
Group type: COMPARATOR
Intervention: Control group (no behaviour change counselling).
Number of subjects: 1827
Study 20022460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating Platform (RP) total knee arthroplasty
Number of subjects: 49
Study 20022460 — intervention group
Group type: COMPARATOR
Intervention: Fixed Bearing (FB) total knee arthroplasty
Number of subjects: 49
Study 18580887 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of plant protein
Number of subjects: 810
Study 18580887 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of fruits and vegetables
Number of subjects: 810
Study 18580887 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of plant protein and fruits and vegetables
Number of subjects: 810
Study 16176119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib with rifampicin
Number of subjects: 0
Study 16176119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib with itraconazole
Number of subjects: 0
Study 16176119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib with metoprolol
Number of subjects: 0
Study 14555369 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine for headache
Number of subjects: 5205
Study 14555369 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine for stomach ache
Number of subjects: 5205
Study 14555369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain reliever use
Number of subjects: 5205
Study 14555369 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported medicine use trend
Number of subjects: 5205
Study 14555369 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent users of medicine
Number of subjects: 5205
Study 10506087 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stories that were readily comprehensible
Number of subjects: 0
Study 10506087 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual stories with a mental framework (provided by relevant visual cues)
Number of subjects: 0
Study 10506087 — intervention group
Group type: COMPARATOR
Intervention: Unusual stories without prior knowledge (no visual cues)
Number of subjects: 0
Study 10506087 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues (relevant, irrelevant, or none) provided before the story
Number of subjects: 0
Study 10506087 — intervention group
Group type: EXPERIMENTAL
Intervention: PET results showing brain activation
Number of subjects: 0
Study 10506087 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial ventral orbitofrontal cortex and left temporal pole activations
Number of subjects: 0
Study 10506087 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial parietal cortex (precuneus) and left prefrontal cortex
Number of subjects: 0
Study 8606475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (three doses: 10 mg/kg intravenously followed by 5 mg/kg at 24 and 48 hours; n = 12)
Number of subjects: 34
Study 8606475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (one dose: 10 mg/kg intravenously; n = 11)
Number of subjects: 34
Study 8606475 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 11)
Number of subjects: 34
Study 8606475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (three doses)
Number of subjects: 34
Study 2019086 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% zinc citrate dentifrice
Number of subjects: 1210
Study 2019086 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice without zinc citrate
Number of subjects: 1210
Study 6775327 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 9
Study 6775327 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg d-amphetamine
Number of subjects: 9
Study 6775327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30303394 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 39
Study 30303394 — intervention group
Group type: COMPARATOR
Intervention: Health training
Number of subjects: 39
Study 28291552 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 501
Number of subjects: 347
Study 28291552 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 347
Study 25769303 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 44
Study 25769303 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir
Number of subjects: 44
Study 23296183 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (20mg)
Number of subjects: 12
Study 23296183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21497767 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine 50 mg/kg body weight PO
Number of subjects: 20
Study 21497767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18007268 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (5 cm H2O) applied during the first 5 hours after intubation
Number of subjects: 40
Study 18007268 — intervention group
Group type: COMPARATOR
Intervention: Hi-Lo tube (HL group)
Number of subjects: 40
Study 18007268 — intervention group
Group type: COMPARATOR
Intervention: SealGuard tube (SG group)
Number of subjects: 40
Study 18007268 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro testing with positive expiratory pressure
Number of subjects: 40
Study 16649459 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% plain lidocaine
Number of subjects: 0
Study 16649459 — intervention group
Group type: COMPARATOR
Intervention: 0.25% plain bupivacaine
Number of subjects: 0
Study 12956748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragranced aerosol products (two types)
Number of subjects: 0
Study 12956748 — intervention group
Group type: COMPARATOR
Intervention: Clean air control
Number of subjects: 0
Study 11192231 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA albuterol
Number of subjects: 63
Study 11192231 — intervention group
Group type: COMPARATOR
Intervention: CFC albuterol
Number of subjects: 63
Study 1312907 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH, 2.5 g given i.v.) pretreatment prior to cisplatin infusion
Number of subjects: 12
Study 1312907 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP, 80 mg/m2) alone
Number of subjects: 12
Study 1312907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP, 80 mg/m2) with GSH pretreatment
Number of subjects: 12
Study 3899093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg purified porcine relaxin vaginally applied on the day of embryo transfer and again 3 days later
Number of subjects: 96
Study 3899093 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo) vaginally applied on the day of embryo transfer and again 3 days later
Number of subjects: 96
Study 3899093 — intervention group
Group type: COMPARATOR
Intervention: Concurrent treatment outside the trial (not specified)
Number of subjects: 96
Study 31613356 — intervention group
Group type: EXPERIMENTAL
Intervention: IGMKK16E7 low-dose (0.5 g/day)
Number of subjects: 41
Study 31613356 — intervention group
Group type: EXPERIMENTAL
Intervention: IGMKK16E7 middle-dose (1 g/day)
Number of subjects: 41
Study 31613356 — intervention group
Group type: EXPERIMENTAL
Intervention: IGMKK16E7 high-dose (1.5 g/day)
Number of subjects: 41
Study 31613356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 28586086 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgressions against bullies
Number of subjects: 160
Study 28586086 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgressions against friends
Number of subjects: 160
Study 28586086 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgressions against disliked peers
Number of subjects: 160
Study 28586086 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral transgressions across relationships
Number of subjects: 160
Study 26214184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle change interventions with ongoing, group-based support
Number of subjects: 84
Study 26214184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle change interventions
Number of subjects: 84
Study 24912062 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 151
Study 24912062 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 151
Study 24912062 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 151
Study 24912062 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive Employment
Number of subjects: 151
Study 22437088 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training program (n=140; 8 weeks, 60-79% HR max reserve, 45-60 minutes, work/rest ratio of 1:1)
Number of subjects: 245
Study 22437088 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (n=105)
Number of subjects: 245
Study 19731310 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics (UDS) treatment
Number of subjects: 0
Study 19731310 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment based on symptoms alone
Number of subjects: 0
Study 18786316 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 94
Study 18786316 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injection (MDI)
Number of subjects: 94